Raymond James Financial Inc. Purchases New Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Raymond James Financial Inc. bought a new position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 10,148 shares of the company’s stock, valued at approximately $76,000.

Several other institutional investors have also modified their holdings of EYPT. Charles Schwab Investment Management Inc. boosted its holdings in shares of EyePoint Pharmaceuticals by 33.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 191,165 shares of the company’s stock valued at $1,424,000 after buying an additional 48,402 shares during the period. Levin Capital Strategies L.P. lifted its position in EyePoint Pharmaceuticals by 440.0% in the 4th quarter. Levin Capital Strategies L.P. now owns 54,000 shares of the company’s stock valued at $402,000 after acquiring an additional 44,000 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in EyePoint Pharmaceuticals by 22.2% in the 4th quarter. Bank of New York Mellon Corp now owns 204,260 shares of the company’s stock worth $1,522,000 after purchasing an additional 37,054 shares during the period. Rhumbline Advisers increased its holdings in EyePoint Pharmaceuticals by 16.1% during the 4th quarter. Rhumbline Advisers now owns 89,560 shares of the company’s stock worth $667,000 after purchasing an additional 12,443 shares in the last quarter. Finally, Deltec Asset Management LLC acquired a new stake in shares of EyePoint Pharmaceuticals in the 4th quarter valued at about $151,000. Institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Trading Up 12.1 %

NASDAQ EYPT opened at $5.38 on Monday. EyePoint Pharmaceuticals, Inc. has a 12 month low of $3.91 and a 12 month high of $22.30. The stock has a 50 day moving average of $6.04 and a 200-day moving average of $7.91. The company has a market cap of $369.76 million, a PE ratio of -2.69 and a beta of 1.39.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.10). The firm had revenue of $11.60 million during the quarter, compared to analyst estimates of $11.02 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. As a group, sell-side analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Citigroup assumed coverage on EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $33.00 price target for the company. Chardan Capital reiterated a “buy” rating and issued a $33.00 price objective on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Finally, StockNews.com upgraded shares of EyePoint Pharmaceuticals to a “sell” rating in a report on Friday, March 14th. One equities research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.63.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.